Muscle-enriched microRNA-486-mediated regulation of muscular atrophy and exercise
- PMID: 39222208
- DOI: 10.1007/s13105-024-01043-w
Muscle-enriched microRNA-486-mediated regulation of muscular atrophy and exercise
Abstract
The objectives of this review were to understand the impact of microRNA-486 on myogenesis and muscle atrophy, and the change of microRNA-486 following exercise, and provide valuable information for improving muscle atrophy based on exercise intervention targeting microRNA-486. Muscle-enriched microRNAs (miRNAs), also referred to as myomiRs, control various processes in skeletal muscles, from myogenesis and muscle homeostasis to different responses to environmental stimuli such as exercise. MicroRNA-486 is a miRNA in which a stem-loop sequence is embedded within the ANKYRIN1 (ANK1) locus and is strictly conserved across mammals. MicroRNA-486 is involved in the development of muscle atrophy caused by aging, immobility, prolonged exposure to microgravity, or muscular and neuromuscular disorders. PI3K/AKT signaling is a positive pathway, as it increases muscle mass by increasing protein synthesis and decreasing protein degradation. MicroRNA-486 can activate this pathway by inhibiting phosphatase and tensin homolog (PTEN), it may also indirectly inhibit the HIPPO signaling pathway to promote cell growth. Exercises regulate microRNA-486 expression both in blood and muscle. This review focused on the recent elucidation of sarcopenia regulation by microRNA-486 and its effects on pathological states, including primary muscular disease, secondary muscular disorders, and age-related sarcopenia. Additionally, the role of exercise in regulating skeletal muscle-enriched microRNA-486 was highlighted, along with its physiological significance. Growing evidence indicates that microRNA-486 significantly impacts the development of muscle atrophy. MicroRNA-486 has great potential to become a therapeutic target for improving muscle atrophy through exercise intervention.
Keywords: Aging; Exercise; Muscle atrophy; Sarcopenia; microRNA-486.
© 2024. The Author(s) under exclusive licence to University of Navarra.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: As no human participants or animal subjects were included in this study, ethics approval and informed consent were not required. Competing interests: The authors have no relevant financial or non-financial interests to disclose.
References
-
- Emery AEH (2002) The muscular dystrophies. Lancet 359:687–695. https://doi.org/10.1016/S0140-6736(02)07815-7 - DOI - PubMed
-
- Kang PB, Griggs RC (2015) Advances in muscular dystrophies. JAMA Neurol 72:741–742. https://doi.org/10.1001/jamaneurol.2014.4621 - DOI - PubMed
-
- Wang XH (2013) MicroRNA in myogenesis and muscle atrophy. Curr Opin Clin Nutr Metab Care 16:258–266. https://doi.org/10.1097/MCO.0b013e32835f81b9 - DOI - PubMed - PMC
-
- Goljanek-Whysall K, Sweetman D, Münsterberg AE (2012) MicroRNAs in skeletal muscle differentiation and disease. Clin Sci (Lond) 123:611–625. https://doi.org/10.1042/CS20110634 - DOI - PubMed
-
- Tüfekci KU, Meuwissen RLJ, Genç S (2014) The role of microRNAs in biological processes. Methods Mol Biol 1107:15–31. https://doi.org/10.1007/978-1-62703-748-8_2 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials